Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,336 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07289997RecruitingPhase 2
Combination therapy for advanced AFP-producing gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
Shijiazhuang, HebeiAges 18 years+ - NCT07294664RecruitingPhase 2
Drug combo trial for first treatment of advanced stomach cancer
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
Zhengzhou, HenanAges 18 years+ - NCT07291063Recruiting
Immunotherapy plus chemo for advanced bile duct or gallbladder cancer
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
Shanghai, Shanghai MunicipalityAges 18–90 - NCT07292961Recruiting
Exercise program for people with scleroderma
This study tests if a special exercise program based on your body and mind can help people with scleroderma feel better. It is for both children (ages 7-18) and adults.
Ankara, AltındağAges 7 years+ - NCT07291076RecruitingPhase 1/Phase 2
Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85 - NCT07284992RecruitingPhase 2
Comparing short vs long radiation with immunotherapy for rectal cancer
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
Jinan, ShandongAges 18–80 - NCT07283367RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
GuangzhouAges 18 years+ - NCT07285434Enrolling by invitationEarly Phase 1
Personalized vaccine for first-line advanced lung cancer
This study tests a personalized vaccine (Microlyvaq™) made just for your tumor, given together with standard chemo and immunotherapy (pembrolizumab). It is for people with advanced non-small cell lung cancer who have not yet started treatment for the advanced stage.
Thessaloniki, MacedoniaAges Any age - NCT07282262RecruitingPhase 2
Ivosidenib for advanced bile duct cancer with IDH1 mutation
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
BeijingAges 18–80 - NCT07284836RecruitingPhase 2
Chemo directly to liver for breast cancer
This trial tests a new way to give chemotherapy directly to the liver for breast cancer that has spread only there. It's for people who have already tried two or more standard treatments.
Hangzhou, ZhejiangAges 18–70 - NCT03899428RecruitingPhase 2
Immune therapy versus targeted therapy for advanced liver cancer
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hong Kong, Hong Kong SARAges 18 years+ - NCT07277322RecruitingPhase 1/Phase 2
Two immunotherapy drugs before surgery for MSS colorectal cancer with liver spots
This trial tests a combination of two immunotherapy drugs (Dupilumab and Toripalimab) before surgery for people with MSS colorectal cancer that has spread to the liver. The goal is to see if this treatment can shrink the liver tumors and help the body's immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT06891742RecruitingPhase 1
A study of a new cell therapy for advanced liver cancer
This trial tests a new treatment called OriC902 for people with advanced liver cancer (HCC) that has not responded to standard therapies. The treatment uses special immune cells designed to target a protein called GPC3 found on cancer cells. The goal is to see if this approach can help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18–75 - NCT07265674RecruitingPhase 3
Study of nanvuranlat for advanced bile duct cancer
This study tests a new drug called nanvuranlat for people with advanced bile duct cancer that has gotten worse after platinum-based chemotherapy. It compares nanvuranlat with the doctor's choice of standard treatments to see which works better.
Duarte, CaliforniaAges 18 years+ - NCT06896890RecruitingPhase 1/Phase 2
Inhaled cisplatin for stage IV lung cancer
This trial tests a new way to give the chemotherapy drug cisplatin—as a dry powder you inhale—for people with stage IV non-small cell lung cancer who have not yet started treatment. The goal is to see if this inhaled form is safe and effective when added to standard immunotherapy or chemotherapy.
BrusselsAges 18 years+ - NCT07260188Recruiting
Breast cancer organoids from patients before chemo
This study collects tumor tissue from breast cancer patients before they start chemotherapy to grow miniature versions of their tumors (organoids) in the lab. The goal is to understand how each tumor responds to treatment, which may help personalize future therapies.
Pavia, PVAges 18 years+ - NCT07267806RecruitingPhase 3
Camrelizumab and Apatinib with or without chemo for advanced liver cancer
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
Guangzhou, GuangdongAges 18 years+ - NCT07253142RecruitingPhase 2
Study of HLX43 with Serplulimab for advanced lung cancer
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
Hefei, AnhuiAges 18–75 - NCT07258979RecruitingPhase 1/Phase 2
YL201 and Toripalimab with or without Cisplatin for Nasopharyngeal Cancer
This trial tests a new drug combination for people with advanced or recurrent nasopharyngeal cancer. It aims to see if YL201 plus Toripalimab (and sometimes cisplatin) can help when standard treatments are not an option.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07254585RecruitingPhase 2
SYS6010 plus enlonstobart for head and neck cancer
This trial is testing a new combination treatment, SYS6010 plus enlonstobart, for people with head and neck squamous cell carcinoma that has come back or spread. It aims to see if this combination works better than enlonstobart alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07258108RecruitingPhase 2
Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18–75 - NCT05255302RecruitingPhase 2/Phase 3
Shorter immune maintenance for stage IV lung cancer after initial treatment
This trial tests whether giving immune therapy maintenance for a shorter time helps people with stage IV non-small cell lung cancer (NSCLC) who are doing well after initial chemo-immunotherapy. It aims to keep the cancer controlled while possibly reducing treatment exposure and side effects.
Aix-en-ProvenceAges 18–74 - NCT07247227Recruiting
Sugemalimab plus chemotherapy for advanced lung cancer
This trial tests a new immunotherapy drug (sugemalimab) combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It aims to see if this combination works well in real-world patients.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,336 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.